A detailed history of Capital International, Inc. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Capital International, Inc. holds 624,895 shares of BGNE stock, worth $111 Million. This represents 1.85% of its overall portfolio holdings.

Number of Shares
624,895
Previous 855,134 26.92%
Holding current value
$111 Million
Previous $122 Million 14.99%
% of portfolio
1.85%
Previous 1.69%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$143.93 - $224.51 $33.1 Million - $51.7 Million
-230,239 Reduced 26.92%
624,895 $140 Million
Q2 2024

Aug 13, 2024

SELL
$129.52 - $174.32 $418,349 - $563,053
-3,230 Reduced 0.38%
855,134 $122 Million
Q1 2024

May 14, 2024

BUY
$141.8 - $181.47 $6.89 Million - $8.82 Million
48,615 Added 6.0%
858,364 $134 Million
Q4 2023

Feb 13, 2024

SELL
$158.67 - $201.58 $6.26 Million - $7.96 Million
-39,482 Reduced 4.65%
809,749 $146 Million
Q3 2023

Nov 13, 2023

SELL
$179.87 - $225.13 $12.6 Million - $15.8 Million
-70,205 Reduced 7.64%
849,231 $153 Million
Q2 2023

Aug 11, 2023

SELL
$178.3 - $266.78 $13.8 Million - $20.7 Million
-77,606 Reduced 7.78%
919,436 $164 Million
Q1 2023

May 15, 2023

SELL
$215.53 - $274.5 $21.7 Million - $27.7 Million
-100,857 Reduced 9.19%
997,042 $215 Million
Q4 2022

Feb 14, 2023

SELL
$125.51 - $229.3 $3.8 Million - $6.95 Million
-30,290 Reduced 2.68%
1,097,899 $241 Million
Q3 2022

Nov 14, 2022

SELL
$131.8 - $202.24 $1.98 Million - $3.04 Million
-15,016 Reduced 1.31%
1,128,189 $152 Million
Q2 2022

Aug 15, 2022

BUY
$121.11 - $216.05 $271,891 - $485,032
2,245 Added 0.2%
1,143,205 $185 Million
Q1 2022

May 16, 2022

BUY
$146.52 - $269.56 $20.7 Million - $38 Million
141,133 Added 14.12%
1,140,960 $215 Million
Q4 2021

Feb 14, 2022

SELL
$248.56 - $389.34 $3.06 Million - $4.79 Million
-12,308 Reduced 1.22%
999,827 $271 Million
Q3 2021

Nov 15, 2021

BUY
$249.6 - $403.14 $18.5 Million - $29.9 Million
74,276 Added 7.92%
1,012,135 $367 Million
Q2 2021

Aug 16, 2021

SELL
$292.75 - $367.01 $28.7 Million - $36 Million
-98,071 Reduced 9.47%
937,859 $322 Million
Q1 2021

May 14, 2021

BUY
$260.64 - $382.12 $11.4 Million - $16.8 Million
43,920 Added 4.43%
1,035,930 $361 Million
Q4 2020

Feb 16, 2021

SELL
$221.31 - $316.61 $23.5 Million - $33.7 Million
-106,344 Reduced 9.68%
992,010 $256 Million
Q3 2020

Nov 13, 2020

SELL
$189.18 - $286.44 $2.91 Million - $4.41 Million
-15,388 Reduced 1.38%
1,098,354 $315 Million
Q2 2020

Aug 14, 2020

BUY
$123.9 - $195.41 $9.47 Million - $14.9 Million
76,470 Added 7.37%
1,113,742 $210 Million
Q1 2020

May 15, 2020

BUY
$121.84 - $173.19 $9.32 Million - $13.3 Million
76,509 Added 7.96%
1,037,272 $128 Million
Q4 2019

Feb 18, 2020

SELL
$115.78 - $208.34 $753,843 - $1.36 Million
-6,511 Reduced 0.67%
960,763 $159 Million
Q3 2019

Nov 14, 2019

BUY
$120.61 - $148.29 $75 Million - $92.3 Million
622,156 Added 180.27%
967,274 $118 Million
Q2 2019

Aug 14, 2019

BUY
$113.99 - $146.86 $3.66 Million - $4.72 Million
32,128 Added 10.26%
345,118 $42.8 Million
Q1 2019

May 15, 2019

BUY
$122.82 - $151.83 $14.4 Million - $17.8 Million
117,318 Added 59.96%
312,990 $41.3 Million
Q4 2018

Feb 14, 2019

BUY
$107.01 - $175.15 $20.9 Million - $34.3 Million
195,672 New
195,672 $27.4 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $18.4B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Capital International, Inc. Portfolio

Follow Capital International, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Capital International, Inc. with notifications on news.